BeiGene
BGNE
#921
Rank
A$33.44 B
Marketcap
$305.72
Share price
0.49%
Change (1 day)
32.17%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$25.02

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$27.54. In 2022 the company made an earnings per share (EPS) of -$32.06 a decrease over its 2021 EPS that were of -$25.17.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$25.02-21.96%
2022-$32.0627.35%
2021-$25.17-19.96%
2020-$31.4520.81%
2019-$26.0431.52%
2018-$19.80417.57%
2017-$3.82-37.16%
2016-$6.09158.95%
2015-$2.35

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.66-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.45-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA